中国经济网北京2月22日讯 广济药业(000952.SZ)近日发布2026年向特定对象发行A股股票预案。公司本次发行拟 募集资金总额不超过60,000.00万元（含本数），扣除发行费用后用于偿还借款和补充流动资金。 本次向特定对象发行股票的发行对象为长江产业集团，拟以现金方式全额认购公司本次向特定对象发行的股 票。 本次向特定对象发行股票的定价基准日为第十一届董事会第十五次（临时）会议公告日。本次发行的发行价格 为6.32元/股，不低于定价基准日前二十个交易日公司股票交易均价的80%（定价基准日前二十个交易日股票交易均 价=定价基准日前二十个交易日股票交易总额/定价基准日前二十个交易日股票交易总量）。 本次发行股票数量不超过94,936,708股（含本数），不超过本次发行前公司总股本的30%，最终发行数量将在本 次发行通过深交所审核并经中国证监会同意注册后，按照相关规定，由上市公司股东会授权董事会根据中国证监会 相关规定及实际认购情况与保荐机构（主承销商）协商确定。 本次向特定对象发行的股票种类为人民币普通股（A股），每股面值为人民币1.00元。本次发行采取向特定对象 发行的方式。公司将在深交所审核通过并取得 ...

Core Viewpoint - Wenzhou Hongfeng plans to raise up to 450 million yuan through a private placement of A-shares to fund expansion projects in lithium battery copper foil and semiconductor etching lead frames [1] Group 1: Fundraising Details - The total amount to be raised is capped at 45,000,000 yuan, net of issuance costs, and will be allocated to specific projects [1] - The shares will be issued as domestic listed RMB ordinary shares (A-shares) with a par value of 1.00 yuan per share [1] - The issuance will be conducted through a private placement to no more than 35 specific investors, including qualified institutional investors [1][2] Group 2: Issuance Process - The final issuance targets will be determined by the company's board based on the inquiry results after approval from the Shenzhen Stock Exchange and the China Securities Regulatory Commission [2] - The number of shares issued will not exceed 30% of the company's total share capital after excluding treasury shares, amounting to a maximum of 149,093,466 shares [2] - The pricing will be based on 80% of the average trading price over the 20 trading days prior to the pricing benchmark date [2] Group 3: Shareholding Structure - As of December 31, 2025, the actual controller, Chen Xiao, holds 156,138,612 shares, representing 31.42% of the company, while his spouse, Lin Ping, holds 15,444,000 shares, totaling 34.53% [3] - Even if Chen Xiao and Lin Ping do not subscribe to the new shares, their combined ownership will still allow them to maintain control of the company post-issuance [3] Group 4: Shareholder Reduction Plan - Chen Xiao plans to reduce his holdings by up to 14.9 million shares within a three-month window, representing a maximum of 3% of the total share capital [4] - The reduction will occur through a combination of centralized bidding and block trading, with specific limits on each method [4] Group 5: Historical Shareholding Changes - Chen Xiao's current holdings amount to 156,138,612 shares, and based on the closing price of 8.85 yuan, he could realize approximately 132 million yuan from this reduction [5] - Since his first reduction in May 2015, he has cumulatively sold 44.18 million shares, generating around 42.4 million yuan in cash [5]

Group 1 - The core point of the article is that Southwest Securities (600369.SH) has disclosed a plan to issue A-shares to specific investors, including Yufu Holdings and Chongqing Water Environment Group, with a total fundraising target of up to 6 billion yuan [1] - The specific investors include no more than 35 parties, with Yufu Holdings committing to subscribe for 1.5 billion yuan and Chongqing Water Environment Group for 1 billion yuan [1] - The total amount raised from the issuance will be used entirely to supplement the company's capital [1]

北京商报讯（记者 刘宇阳 实习生 姚榕琰）2月13日，西南证券发布2026年度向特定对象发行A股股票募集资金使用的可行性分析报告。公司拟向包括重庆渝 富控股集团及其一致行动人重庆水务环境控股集团在内的特定对象发行A股股票数量不超过约19.94亿股，募集资金总额不超过人民币60亿元，扣除发行费用 后拟全部用于增加公司资本金。 | 序号 | 募集资金投向 | | --- | --- | | 1 | 财富管理业务 | | 2 | 投资银行业务 | | 3 | 资产管理业务 | | ব | 证券投资业务 | 具体用途来看，主要用于财富管理业务不超过5亿元，投资银行业务不超过2.5亿元，资产管理业务不超过9亿元，证券投资业务不超过15亿元，增加子公司 投入不超过6亿元，信息技术与合规风控建设不超过7.5亿元，偿还债务及补充其他营运资金不超过15亿元。 ...

Core Viewpoint - Guangji Pharmaceutical (000952) plans to raise up to 600 million yuan through a private placement to its controlling shareholder, Changjiang Industrial Group, at a price of 6.32 yuan per share, aimed at optimizing its capital structure and addressing financial pressures [1] Group 1: Fundraising and Financial Strategy - The funds raised will be used to repay loans and supplement working capital, with the company's debt-to-asset ratio standing at 62.67% as of September 30, 2025 [1] - The controlling shareholder's stake will increase from 25.26% to 41.33%, indicating strong support for the company [1] Group 2: Performance Forecast - The company anticipates a net loss of between 399 million yuan and 518 million yuan for 2025, marking the third consecutive year of losses, following losses of 140 million yuan in 2023 and 295 million yuan in 2024 [1] - Revenue has declined for two consecutive years, with 2024 revenue reported at 639 million yuan, a year-on-year decrease of 13.42% [3] Group 3: Recent Developments - On February 13, 2026, the company announced the receipt of a drug registration certificate for Mecobalamin tablets, which are used for the treatment of peripheral neuropathy [1] - The company also faces potential shareholder compensation risks due to possible information disclosure issues [1] Group 4: Market Performance - Over the past week (February 9 to 13, 2026), Guangji Pharmaceutical's stock price has shown a slight upward trend, with a price increase of 1.64% and a trading range fluctuation of 5.29% [2] - On February 13, the stock closed at 8.07 yuan, up 1.51%, with a trading volume of 94.31 million yuan and a turnover rate of 3.35% [2] - Technical indicators suggest a weak bullish signal, with the stock touching the upper Bollinger Band at 8.33 yuan [2] Group 5: Institutional Insights - Overall institutional ratings are neutral, with no significant bullish or bearish views [4] - The fund holding ratio is only 0.04%, indicating low institutional interest and activity [4] - Market attention remains moderate, with no clear directional guidance from public sentiment regarding short-term events [4]

经济观察网国林科技（300786）披露向特定对象发行A股股票预案，拟向控股股东、实际控制人丁香鹏 定增募资不超过2.24亿元，用于补充流动资金。该事件引发市场关注，公司股价近期出现震荡波动。 近期事件 2026年2月11日晚，国林科技披露向特定对象发行A股股票预案，拟以13.56元/股向控股股东、实际控制 人丁香鹏定增募资不超过2.24亿元，扣除发行费用后全部用于补充流动资金。丁香鹏全额现金认购，发 行完成后其持股比例将进一步提升，以优化公司现金流结构、降低资产负债率并支持业务拓展。该事件 于2月12日引发市场关注，公司股价当日小幅下跌。 股票近期走势 近7天，国林科技股价震荡波动。定增预案披露后，2月12日收盘价16.53元，较前一日下跌0.78%；截至 2月13日最新数据，股价回升至16.60元，当日涨跌幅0.42%。区间内累计涨幅1.97%，最高价16.85元， 最低价16.45元，成交量和换手率在2月12日显著放大。技术面显示，股价短期处于震荡区间。 财报分析 定增背景与公司近期财务状况相关。2022年至2025年1—9月，国林科技营业收入持续增长，但经营活动 现金流净额自2023年起持续为负。同时， ...

温州宏丰（300283）(300283.SZ)发布2026年度向特定对象发行A股股票预案，本次向特定对象发行A股 股票募集资金总额不超过4.5亿元(含本数)，在扣除发行费用后将应用于锂电铜箔及电子铜箔扩产项目以 及半导体蚀刻引线框架项目。 ...

每经AI快讯，温州宏丰2月12日晚间发布公告称，本次向特定对象发行股票方案已经公司第六届董事会 第八次（临时）会议审议通过，尚需获得公司股东会的批准，最终发行方案以中国证监会准予注册的方 案为准。本次向特定对象发行股票的对象不超过35名（含35名）特定投资者，本次发行的股票数量按照 本次发行募集资金总额除以发行价格确定，且不超过本次发行前剔除库存股后的公司总股本的30%，即 不超过约1.49亿股（含本数）。发行价格不低于本次发行的定价基准日前20个交易日公司股票交易均价 的80%。本次发行拟募集不超过4.5亿元。 每经头条（nbdtoutiao）——打造百万元级尊界的江淮，迎来葛卫东、方文艳联手投资：两人各掏10亿 元，公司股价应声大涨！复盘历史：牛散参与定增有赚也有亏 （记者 张明双） ...

每经AI快讯，2月12日，温州宏丰(300283.SZ)公告称，公司拟向特定对象发行A股股票，募集资金总额 不超过4.5亿元，扣除发行费用后，拟投入锂电铜箔及电子铜箔扩产项目和半导体蚀刻引线框架项目。 （文章来源：每日经济新闻） ...

广济药业主营维生素B2、B6及医药制剂产品，广泛应用于医药原料药、饲料添加剂和食品添加剂等领 域。公司旗下拥有武穴、孟州等四个生产基地，主导产品包括不同等级的核黄素及其衍生物，以及口服 固体制剂和大输液类产品。 经观健康 广济药业（000952）(000952.SZ)近期公布了一项总额不超过6亿元的定向增发方案，旨在从其控股股东 长江产业投资集团获取资金支持。作为全球维生素B2的主要供应商之一，广济药业近期发布2025年业 绩预告，预计全年将出现3.99亿元至5.18亿元的亏损。 根据广济药业发布的《2026年向特定对象发行A股股票预案》，此次定增的发行对象为湖北省国资旗下 的长江产业集团，该集团目前持有公司25.26%的股份，是其主要股东。本次定增定价基准日为第十一 届董事会第十五次(临时)会议决议公告日，发行价格为6.32元/股，不低于前20个交易日股票均价的 80%。拟发行股份数量上限为94,936,708股，不超过公司总股本的30%，最终数量将在通过深交所审核 并获得证监会注册后由公司董事会与保荐机构协商确定。 自2023年以来，由于维生素B2市场价格持续低迷，广济药业已连续三年出现净利润亏损，且亏损 ...